Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
181
-
Total 13F shares, excl. options
-
14.9M
-
Shares change
-
-609K
-
Total reported value, excl. options
-
$1.33B
-
Value change
-
-$64.9M
-
Put/Call ratio
-
0.22
-
Number of buys
-
73
-
Number of sells
-
-92
-
Price
-
$89.22
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q2 2022
209 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q2 2022.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 181 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.9M shares
of 19.3M outstanding shares and own 77.39% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.7M shares), VANGUARD GROUP INC (1.77M shares), JANUS HENDERSON GROUP PLC (1.39M shares), STATE STREET CORP (1.08M shares), MACQUARIE GROUP LTD (784K shares), VILLERE ST DENIS J & CO LLC (496K shares), Stephens Investment Management Group LLC (454K shares), Chicago Capital, LLC (448K shares), DIMENSIONAL FUND ADVISORS LP (443K shares), and abrdn plc (429K shares).
This table shows the top 181 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.